Skip to main content
. 2023 May 10;14:1105180. doi: 10.3389/fimmu.2023.1105180

Figure 2.

Figure 2

Radioimmunotherapy regimens in current clinical trials for patients with metastatic colorectal cancer. (mCRC, metastatic colorectal cancer; D, durvalumab; T, tremelimumab; RT, radiotherapy; N, nivolumab; I, ipilimumab; HFRT, hypofractionated radiation therapy; LDFRT, low-dose fractionated radiation therapy; SBRT, stereotactic body radiotherapy; CPM, cyclophosphamide; AMP, programmed cell death 1 (PD-1) targeting agent AMP-224; WK, week).